Fra et rent økonomisk synspunkt har lægemiddelindustrien nemlig på grund af det lave antal borgere, der rammes af disse sjældne sygdomme, ingen interesse i at påtage sig forskningsudgifter.
In fact, from a commercial point of view the pharmaceutical industry has no interest in committing to research costs, given the low number of people affected by these rare diseases.